Cancer Communications
indexed by SCI
BMC

doi: 10.1186/s40880-017-0184-9
Metformin targets multiple signaling pathways in cancer
Yong Lei, Yanhua Yi, Yang Liu, Xia Liu, Evan T. Keller, Chao-Nan Qian, Jian Zhang and Yi Lu
Key Laboratory of Longevity and Ageing-related Diseases, Ministry of Education; Center for Translational Medicine, Guangxi Medical University
[Abstract] Metformin, an inexpensive and well-tolerated oral agent commonly used in the first-line treatment of type 2 diabetes, has become the focus of intense research as a candidate anticancer agent. Here, we discuss the potential of metformin in cancer therapeutics, particularly its functions in multiple signaling pathways, including AMP-activated protein kinase, mammalian target of rapamycin, insulin-like growth factor, c-Jun N-terminal kinase/mitogen-activated protein kinase (p38 MAPK), human epidermal growth factor receptor-2, and nuclear factor kappaB pathways. In addition, cutting-edge targeting of cancer stem cells by metformin is summarized.
Chinese Journal of Cancer 2017, Volume: 36, Issue 7
[ PDF Full-text ]
[ Html full-text / Citation export] (BioMed Central)

[Google Scholar]


Cite this article

Yong Lei, Yanhua Yi, Yang Liu, Xia Liu, Evan T. Keller, Chao-Nan Qian, Jian Zhang and Yi Lu. Metformin targets multiple signaling pathways in cancer. Chin J Cancer. 2017, 36:17. doi:10.1186/s40880-017-0184-9


Export citations

EndNote


SHARE THIS ARTICLE


Your Comments

  

 


Comments:


CJC Wechat 微信公众号

CJC触屏版


 

Editorial Manager


CC adopts Editorial Manager to manage its submissions from Dec.18, 2014
 

 

Reference style for  

 EndNote,
 Reference Manager



Editorial Manager


 

Year:

 

Month:

Advanced search

Subscription


CJC is now published by BioMed Central

© Chinese Journal of Cancer

Sun Yat-sen University Cancer Center

651 Dongfeng Road East, Guangzhou 510060, P. R. China